

Marco Gerlinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8483038/publications.pdf>

Version: 2024-02-01

53
papers

12,255
citations

201674

27
h-index

223800

46
g-index

61
all docs

61
docs citations

61
times ranked

20186
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. <i>New England Journal of Medicine</i> , 2012, 366, 883-892.	27.0	6,769
2	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. <i>Nature Genetics</i> , 2014, 46, 225-233.	21.4	1,103
3	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. <i>Science</i> , 2014, 346, 251-256.	12.6	962
4	Intratumor Heterogeneity: Seeing the Wood for the Trees. <i>Science Translational Medicine</i> , 2012, 4, 127ps10.	12.4	443
5	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. <i>British Journal of Cancer</i> , 2010, 103, 1139-1143.	6.4	381
6	Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 605-619.	28.4	303
7	Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. <i>Trends in Cancer</i> , 2016, 2, 49-63.	7.4	222
8	Cancer: Evolution Within a Lifetime. <i>Annual Review of Genetics</i> , 2014, 48, 215-236.	7.6	196
9	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 36, 35-50.e9.	16.8	179
10	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. <i>European Urology</i> , 2014, 66, 936-948.	1.9	141
11	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. <i>Lancet Oncology</i> , The, 2010, 11, 358-365.	10.7	116
12	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
13	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. <i>European Urology</i> , 2015, 67, 729-737.	1.9	100
14	Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. <i>Journal of Pathology</i> , 2013, 231, 424-432.	4.5	93
15	Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. <i>Journal of Pathology</i> , 2012, 227, 146-156.	4.5	92
16	Egr-1 Induces the Expression of Its Corepressor Nab2 by Activation of the Nab2 Promoter Thereby Establishing a Negative Feedback Loop. <i>Journal of Biological Chemistry</i> , 2005, 280, 42785-42793.	3.4	83
17	Parallel evolution of tumour subclones mimics diversity between tumours. <i>Journal of Pathology</i> , 2013, 230, 356-364.	4.5	79
18	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. <i>European Journal of Cancer</i> , 2010, 46, 2166-2177.	2.8	71

#	ARTICLE	IF	CITATIONS
19	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. <i>Genome Biology</i> , 2014, 15, 433.	8.8	69
20	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibusatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
21	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6924-6934.	7.0	62
22	Identifying key questions in the ecology and evolution of cancer. <i>Evolutionary Applications</i> , 2021, 14, 877-892.	3.1	58
23	Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. <i>Current Opinion in Genetics and Development</i> , 2015, 30, 1-6.	3.3	57
24	The promise of circulating tumor cell analysis in cancer management. <i>Genome Biology</i> , 2014, 15, 448.	8.8	47
25	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. <i>Clinical Chemistry</i> , 2018, 64, 1626-1635.	3.2	46
26	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. <i>Nature Communications</i> , 2020, 11, 139.	12.8	44
27	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. <i>Genome Medicine</i> , 2010, 2, 53.	8.2	43
28	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 72-82.	4.4	40
29	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. <i>European Journal of Cancer</i> , 2020, 136, 99-106.	2.8	31
30	Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. <i>BMC Medicine</i> , 2016, 14, 185.	5.5	29
31	Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. <i>Journal of Immunology</i> , 2006, 177, 8212-8218.	0.8	24
32	Computational optimisation of targeted DNA sequencing for cancer detection. <i>Scientific Reports</i> , 2013, 3, 3309.	3.3	20
33	Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough. <i>Cancer Cell</i> , 2021, 39, 16-18.	16.8	18
34	Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy. <i>European Journal of Cancer</i> , 2010, 46, 2913-2918.	2.8	17
35	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. <i>Nature Ecology and Evolution</i> , 2021, 5, 1024-1032.	7.8	16
36	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. <i>Cancers</i> , 2019, 11, 736.	3.7	15

#	ARTICLE	IF	CITATIONS
37	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 88-98.	6.3	15
38	Multiplexed single cell protein expression analysis in solid tumours using a miniaturised microfluidic assay. <i>Convergent Science Physical Oncology</i> , 2017, 3, 024003.	2.6	13
39	Targeted drugs ramp up cancer mutability. <i>Science</i> , 2019, 366, 1452-1453.	12.6	13
40	Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. <i>Haematologica</i> , 2010, 95, 1130-1135.	3.5	10
41	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. <i>Clinical Colorectal Cancer</i> , 2019, 18, 64-71.e1.	2.3	10
42	Metastasis Seeding Cells: Lone Invaders or Mass Migrators?. <i>Clinical Cancer Research</i> , 2018, 24, 2032-2034.	7.0	7
43	Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. , 2022, 39, .		7
44	Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 971-972.	1.6	6
45	Cancer (r)evolution. <i>Nature Ecology and Evolution</i> , 2017, 1, 1051-1052.	7.8	6
46	Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. <i>Cancers</i> , 2020, 12, 3736.	3.7	6
47	Effect of perioperative FLOT <i>versus</i> ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. <i>BJS Open</i> , 2022, 6, .	1.7	3
48	Genetic Intratumor Heterogeneity. , 2015, , 571-593.		2
49	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020, 10, 1634.	2.8	2
50	Translating Seminoma Genomic Landscapes into Clinical Practice. <i>European Urology</i> , 2015, 68, 84-85.	1.9	0
51	Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.. <i>Blood</i> , 2008, 112, 3251-3251.	1.4	0
52	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022, 82, PR012-PR012.	0.9	0
53	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022, 82, A002-A002.	0.9	0